Aldara - Imiquimod 5% + IDH1R132H-vac + Vorasidenib hemicitric acid hemihydrate for astrocytoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Oct 2026: Trial registered, NCT07877415

The trials

NCT07877415: A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)

State
Not started
Phase
Phase 1
People
45 planned
Started
1 Jan 2027
Primary completion
31 Dec 2032
Arms
Safety Lead-in, Main Therapy, Primary Treatment - Arm 2, Main Therapy, Secondary Treatment
Results
None posted
  1. 16 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.